Health Care Services

GeneDx

GeneDx released FY2026 Q1 earnings on May 4 After-Market EST, actual revenue USD 102.25 M (forecast USD 112.45 M), actual EPS USD -2.1583 (forecast USD -0.56)

GeneDx to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 112.45 M, EPS USD -0.56

Keith A. Meister Increases Stake in GeneDx Holdings Corp.

GeneDx released FY2025 earnings on February 23 Pre-Market (EST), actual revenue USD 427.54 M (forecast USD 426.96 M), actual EPS USD -0.7339 (forecast USD -0.51)

GeneDx released FY2025 Q4 earnings on February 23 Pre-Market (EST), actual revenue USD 120.99 M (forecast USD 120.44 M), actual EPS USD -0.6081 (forecast USD -0.385)

GeneDx Reports 2025 Fiscal Year Performance, Reaffirms 2026 Revenue Guidance

GeneDx to release FY2025 Q4 earnings on February 23 Pre-Market EST, forecast revenue USD 120.44 M, EPS USD -0.385

GeneDx Holdings Showcases Rare Disease Diagnostic Platform GeneDx Infinity

GeneDx Holdings Corp. projects 2026 revenue between $540M and $555M

GeneDx Holdings Corp. Launches GenomeDx Prenatal™ Prenatal Whole Genome Sequencing Service

GeneDx Holdings Corp. Publishes Record Number of Rare Disease Genomics Studies in 2025

ARK Invest ETF Significant 增持 Genomics and Autonomous Vehicle Stocks

Handelsbanken Fonder AB Increases Holdings in GeneDx Holdings Corp.

New Jersey Police and Firemen's Retirement System Increases GeneDx Holdings Stake

Joshua Ruch Reports Sale of Genedx Holdings Corp. Common Stock

GeneDx Receives Multiple Buy Ratings from Brokers

GeneDx Holdings Corp. to Showcase Genetic Disease Discoveries at NSGC Annual Meeting

GeneDx released FY2025 Q3 earnings on October 28 Pre-Market (EST), actual revenue USD 116.74 M (forecast USD 104.67 M), actual EPS USD -0.2699 (forecast USD 0.2025)

GeneDx released FY2025 9 Months Earnings on October 28 Pre-Market EST, with actual revenue of USD 306.55 M and EPS of USD -0.137

GeneDx Holdings Reports EPS of $0.37

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ARKG

LABU

IDNA

Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ: WGS) regarding potential securities fraud or unlawful business practices by the company and its officers. GeneDx recently reported Q1 2026 financial results, revealing total revenue of $102.3 million but reduced its full-year revenue guidance to $475-$490 million, down from $540-$555 million. Following this news, GeneDx's stock price plummeted by 49.20% to $34.51 per share on May 5, 2026. Investors are encouraged to contact Pomerantz for more information.

prnewswire

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Genomics Immunology and Healthcare ETF

GeneDx - CW27

20:02 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

SBIO

Keith A. Meister, a 10% owner and director of Genedx Holdings, purchased 1,205,147 shares for $46,806,729 on May 7, 2026. Following this transaction, he controls a total of 4,786,570 Class A common shares, with 20,129 shares held directly and 4,766,441 shares controlled indirectly, as reported in a recent SEC filing.

Fidelity

ALPS Medical Breakthrough

Genedx Holdings Insider Bought Shares Worth $46,806,729, According to a Recent SEC Filing

RKLB

CRWV

NTLA

Cathie Wood's ARK Invest ETFs adjusted their portfolio by increasing investments in AI infrastructure, genomic medicine, and defense technology while reducing holdings in semiconductor and space-related companies. Notable purchases included shares of Intellia Therapeutics, Tempus AI, and GeneDx, while significant sales involved Advanced Micro Devices and Rocket Lab. Overall, ARK's strategy reflects a strong focus on AI and healthcare sectors, with substantial inflows into software and fintech companies as well.

- Cathie Wood’s ARK Invest ETFs recently reduced their investments in semiconductor and space-related companies.  
- They increased their holdings in AI infrastructure, genomic medicine, autonomous systems, defense technology, and software platforms.  
- Notably, the ARK Innovation ETF (ARKK) acquired over 371,000 shares of Intellia Therapeutics (NTLA), amounting to an investment exceeding $5 million.

Rocket Lab

Coreweave

Intellia Therap

Tempus AI

Franklin Genomic Adv ETF

iShares US Digital Infrastructure and Real Estate ETF

T-REX 2X Long CRWV Daily Target ETF

GraniteShares 2x Long AMD Daily ETF

Health Care Select Sector SPDR

ISHRS S&P Glb It

iShares US Medical Devices

ISHRS Aero & Def

Global X Data Center & Dgtl Infrs ETF

Proshares Big Data Refiners ETF

Global X Cloud Computing ETF

ARK Space Exploration & Innovation ETF

Invesco Aero & Defense ETF

Invesco AI and Next Gen Software ETF

Invesco Nasdaq Biotechnology ETF

Wisdomtree BioRevolution Fund ETF

Direxion Daily AMD Bull 2X Shares

SPDR S&P Aerospace & Def

Leverage Shares 2X Long CRWV Daily ETF

iShares US Healthcare Providers

Tradr 2X Long TEM Daily ETF

VG Info Tech

Tradr 2X Long CRWV Daily ETF

Ark Innovation ETF

Cathie Wood's weekly recap: buys TEM, WGS, and CRWV; sells AMD and RKLB

Wall Street Zen downgraded GeneDx (NASDAQ:WGS) from a "hold" to a "sell" rating. Other brokerages have also adjusted their ratings, with Wells Fargo lowering its price target from $155 to $75, while BTIG Research set a new target of $90. GeneDx's stock opened at $40.77, with a 52-week range of $32.21 to $170.87. The company reported a quarterly EPS of ($0.28), missing estimates, and had revenue of $102.25 million. Insider trading activity included a significant purchase by Director Keith A. Meister and a sale by CFO Kevin Feeley.

Market Beat

Nektar Therap

Cidara Therap

Wells Fargo

Piper Sandler Cos

Franklin Resources

Invesco

Sumitomo Mitsui Trust Holdings, Inc.

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

GeneDx (NASDAQ:WGS) Cut to "Sell" at Wall Street Zen

Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ: WGS) regarding potential securities fraud or unlawful business practices. GeneDx recently reported Q1 2026 financial results, revealing total revenue of $102.3 million but reduced its full-year revenue guidance to $475-$490 million, down from $540-$555 million. Following this news, GeneDx's stock price plummeted by 49.20% to $34.51 per share. Investors are encouraged to contact Pomerantz for more information about joining the class action.

MorningStar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

GeneDx Holdings Corp. (NASDAQ:WGS) shares rose 10.7% to $38.43, with trading volume increasing by 182%. Analysts have mixed ratings, with price targets ranging from $70 to $170. The company reported a loss of $0.28 EPS, missing estimates, and revenue of $102.25 million. Insiders sold shares to cover tax obligations, and institutional investors have increased their stakes significantly. GeneDx has a market cap of $1.19 billion and an average rating of "Moderate Buy" from analysts.

Jefferies Financial

GeneDx (NASDAQ:WGS) Trading Up 10.7%  - Here's What Happened

GeneDx Holdings Corp. (NASDAQ:WGS) shares surged 12% after a steep post-earnings sell-off, driven by bargain hunters. The stock had previously dropped nearly 49% due to lowered revenue guidance and disappointing quarterly results. Despite this, the company reported strong growth in exome and genome testing volume. CEO Katherine Stueland highlighted sustained demand for their services. However, the stock remains significantly below key moving averages, indicating a bearish trend. As of Thursday, shares were trading at $38.95, close to their 52-week low of $32.21.

benzinga_article

Shutterstock

Why Is GeneDx Stock Surging Thursday?

Artificial intelligence is gaining traction in healthcare, attracting investors amid inflation and energy cost concerns. This article highlights three stocks: GeneDx Holdings, a genomics company utilizing AI for rare disease testing; Medtronic, a medical device giant integrating AI in surgical tools; and Stryker, known for its AI-assisted surgical platforms. Each company presents unique growth opportunities and challenges, including financial pressures and market competition. Investors interested in AI-driven healthcare innovations should consider these stocks while being mindful of their respective risks and market dynamics.

Simplywall

Stryker

Medtronic

If AI Reshapes Healthcare, These Three Stocks Could Lead

Shares of GeneDx plummeted on Tuesday due to a significant sales miss in the first quarter, which led to a lowered guidance for the fiscal year. The stock dropped by 50%, causing alarm among analysts. The poor performance has raised concerns about the company's financial outlook.

Unusual Whales

The 'Alarming' Results That Caused GeneDx Stock To Plummet 50%

BRBR

IPGP

ADEA

OSIS

ADTN

SHOP

INSP

PCOR

GeneDx(WGS) fell 49.2%, with a trading turnover 393.0 Million USD, and a year-to-date fell 73.5%. Bellring Brands(BRBR) fell 38.77%, with a trading turnover 272.8 Million USD, and a year-to-date fell 60.2%. IPG Photonics(IPGP) fell 25.74%, with a trading turnover 280.2 Million USD, and a year-to-date rose 26.9%.

GeneDx(WGS.US)